Trade AstraZeneca ^AZN

AstraZeneca PLC $AZN Shares Sold by Hsbc Holdings PLC

AstraZeneca PLC $AZN Shares Acquired by Fayez Sarofim & Co

AstraZeneca (LSE:AZN): Assessing Valuation After a Strong Year-to-Date Share Price Rally

Salesforce (CRM) Is Up 11.5% After AI Partnerships, Guidance Hike And Buybacks Completion - Has The Bull Case Changed?

AstraZeneca Announces New AI-Driven Collaboration with MENACTRIMS Aiming to Improve NMOSD Diagnosis Across the Middle East & Africa

TD Cowen Remains a Buy on AstraZeneca (AZN) | Markets Insider

The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup

First Trust Advisors LP Acquires 217,595 Shares of AstraZeneca PLC $AZN

AstraZeneca PLC $AZN Shares Bought by Invesco Ltd.

CW Advisors LLC Increases Stake in AstraZeneca PLC $AZN

1832 Asset Management L.P. Acquires 18,543 Shares of AstraZeneca PLC $AZN

AstraZeneca to bring 10 new cancer medicines by 2030

AstraZeneca PLC $AZN Shares Sold by Capital Fund Management S.A.

Plasma proteomics to explore benefit from anti-PD-(L)1 in advanced solid tumors: a prospective pilot study

SCS Capital Management LLC Purchases 142,331 Shares of AstraZeneca PLC $AZN

Marshall Wace LLP Buys 623,902 Shares of AstraZeneca PLC $AZN

Guggenheim Capital LLC Grows Position in AstraZeneca PLC $AZN - Markets Daily

AstraZeneca PLC $AZN Shares Sold by Epoch Investment Partners Inc. - Markets Daily

Epoch Investment Partners Inc. Trims Position in AstraZeneca PLC $AZN

Neurimmune inks deal to advance NI-009 for AL amyloidosis | BioWorld

Personalized ctDNA detection and genomic profiling in the NeoRHEA Study

Has AstraZeneca's Strong 30% Rally Left Further Upside in 2025?

AstraZeneca (LON:AZN) Given "Overweight" Rating at JPMorgan Chase & Co.

European Shares Gain as Tech Rallies But FTSE 100 Lags | IG AU

AstraZeneca (LON:AZN) Earns "Overweight" Rating from JPMorgan Chase & Co. - Daily Political

Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer

M&T Bank Corp Has $15.30 Million Stock Position in AstraZeneca PLC $AZN - Markets Daily

European Shares Gain as Tech Rallies But FTSE 100 Lags - IG UK

AstraZeneca (AZN) Named One of BofA's Top 25 Stocks for 2026

AstraZeneca share price today - Live NSE/BSE | The Economic Times

Regulatory actions for Dec. 3, 2025 | BioWorld

HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy

Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial

Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations

Foundation model based prediction of lung cancer survival using temporal changes in dual time point CT scans

AstraZeneca (LON:AZN) Share Price Passes Above 200-Day Moving Average - Here's Why

AZD-6750 enhances CD8+ T-cell activity | BioWorld

US announces zero tariff pharmaceutical deal with Britain

UK and US agree on zero-tariff pharma deal after months of tensions | Euronews

US and UK agree zero tariffs deal on pharmaceuticals

10 Best Low Volatility Investments in December 2025

West Family Investments Inc. Acquires 5,051 Shares of AstraZeneca PLC $AZN

J.W. Cole Advisors Inc. Boosts Holdings in AstraZeneca PLC $AZN - Markets Daily

AstraZeneca PLC $AZN Shares Purchased by Scotia Capital Inc.

Laurel Wealth Advisors LLC Purchases 25,830 Shares of AstraZeneca PLC $AZN

AstraZeneca PLC $AZN Shares Sold by Choreo LLC | MarketBeat

How Recent Shifts Are Changing the Analyst Story for AstraZeneca

AZN: Oncology Pipeline Execution And Patent Expiry Risks Will Define Long-Term Prospects

AstraZeneca PLC $AZN Shares Sold by Elevation Point Wealth Partners LLC

Characterisation of human in vitro tumour-associated macrophage models to define translational relevance

Germline variants of the POLH and RAD51 genes are candidate variants associated with risk of hormone receptor-negative young-onset breast cancer

Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial

Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer

HER2-positive Gastric Cancer Clinical Trial Pipeline: Insights into a Growing Landscape with 20+ Companies Advancing Novel Treatments| DelveInsight

Follicular Lymphoma Market Trends, Opportunities, Growth Challenges and Competitive Intelligence 2025-2035

Global Retirement Partners LLC Invests $1.52 Million in AstraZeneca PLC $AZN - Markets Daily

Quadrant Capital Group LLC Grows Stock Holdings in AstraZeneca PLC $AZN - Markets Daily

Financial Advocates Investment Management Sells 5,375 Shares of AstraZeneca PLC $AZN - Markets Daily

Rep. Lisa C. McClain Sells Off Shares of AstraZeneca PLC (NASDAQ:AZN) - Markets Daily

US Medicare Price Cuts: Analysts Predict Minimal Impact of U.S. Medicare Price Cuts on Drugmakers, ETPharma

Rep. Lisa C. McClain Purchases Shares of AstraZeneca PLC (NASDAQ:AZN)

Why Medicare price cuts matter for Novo Nordisk, European pharma

AstraZeneca PLC $AZN Shares Acquired by Thornburg Investment Management Inc. - Markets Daily

JPMorgan Chase & Co. Trims Stock Position in AstraZeneca PLC $AZN

Boston Partners Sells 46,721 Shares of AstraZeneca PLC $AZN

AstraZeneca PLC $AZN Shares Sold by American Century Companies Inc.

Rep. Lisa C. McClain Sells AstraZeneca PLC (NASDAQ:AZN) Shares

CPHI Pharma Expo: Indian Pharma Market Set for Double-Digit Growth Amid Global Interest, ETPharma

FDA Clears AstraZeneca's Imfinzi as First Perioperative Immunotherapy for Gastric Cancers

Analysts Set AstraZeneca PLC (NASDAQ:AZN) PT at $86.00 - Stock Observer

North Star Asset Management Inc. Invests $300,000 in AstraZeneca PLC $AZN - Daily Political

Imfinzi Approved in the US as First and Only Perioperative Immunotherapy for Patients with Early Gastric and Gastroesophageal Cancers

This AI-adjacent FTSE 100 stock could be good to consider for a Stocks and Shares ISA

FourThought Financial Partners LLC Increases Position in AstraZeneca PLC $AZN - Markets Daily

SG Americas Securities LLC Grows Position in AstraZeneca PLC $AZN - Markets Daily

SG Americas Securities LLC Grows Stake in AstraZeneca PLC $AZN - Stock Observer

AstraZeneca (LSE:AZN): Evaluating Valuation Strength After a 36% Total Shareholder Return

4568: Future Oncology Pipeline Success Will Drive Further Upside For Shares

Providence Wealth Advisors LLC Invests $279,000 in AstraZeneca PLC $AZN

AstraZeneca (LON:AZN) Sets New 12-Month High - Time to Buy?

Beyfortus® (nirsevimab) now available in Malaysia to protect all infants against RSV disease

Beyfortus now available in Malaysia to help protect all infants against RSV disease and reduce hospitalisations | Malay Mail

AstraZeneca Expands US Footprint With $2 Billion Maryland Manufacturing Push

AstraZeneca Investment: AstraZeneca Expands Maryland Manufacturing with $2 Billion Investment, ETPharma

Harbour BioMed advances collaboration with AstraZeneca | Markets Insider

A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial

Malaysia approves Sanofi and AstraZeneca's Beyfortus® (nirsevimab)

AstraZeneca PLC (NASDAQ:AZN) Receives $86.00 Average Price Target from Brokerages - Daily Political

Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of AstraZeneca PLC (NASDAQ:AZN) - Daily Political

AstraZeneca PLC $AZN Stock Holdings Lessened by Journey Strategic Wealth LLC - Markets Daily

I asked ChatGPT for the best FTSE 100 stock! Here's what it said…

Cozad Asset Management Inc. Sells 6,105 Shares of AstraZeneca PLC $AZN - Stock Observer

Systematic review of evidence on feasibility of administering intranasal live attenuated influenza vaccine at home

Guerra Pan Advisors LLC Has $664,000 Stock Position in AstraZeneca PLC $AZN - Stock Observer

AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer

AstraZeneca to invest $2 billion as part of US manufacturing push